
==== Front
Adv TherAdv TherAdvances in Therapy0741-238X1865-8652Springer Healthcare Cheshire 3117951597510.1007/s12325-019-00975-wCorrectionCorrection to: A Multicenter, Observational, Prospective Study of the Effectiveness of Switching from Budesonide/Formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler® Syk Jörgen 123Vinge Ines 4Sörberg Mikael 5Vahteristo Mikko 6http://orcid.org/0000-0002-9967-9134Rytilä Paula paula.rytila@orionpharma.com 71 0000 0004 1937 0626grid.4714.6Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden 2 Academic Primary Health Care Centre, Stockholm, Sweden 3 0000 0004 1936 9457grid.8993.bDepartment of Women’s and Children’s Health, Uppsala University, Uppsala, Sweden 4 Asthma-Allergy-Lung Department, Lidingö Hospital, Lidingö, Sweden 5 Orion Pharma, Danderyd, Sweden 6 0000 0004 0400 1289grid.419951.1Orion Corporation, Orion Pharma, Kuopio, Finland 7 0000 0004 0400 1289grid.419951.1Orion Corporation, Orion Pharma, Espoo, Finland 9 6 2019 9 6 2019 2019 36 7 1770 1770 22 2 2019 © The Author(s) 2019Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2019
==== Body
Correction to: Adv Ther 10.1007/s12325-019-00940-7
Unfortunately, the mean difference in change from baseline ACT was incorrectly reported in the abstract as 19.0 vs. 20.8 instead of 18.9 vs. 20.7

The original version of this article was revised.

